BACKGROUND: Bevacizumab is associated with an increased risk of arterial thromboembolism (ATE); however, its effect on venous thromboembolism (VTE) remains controversial. Scant data exist on the factors that increase the risk of ATE/VTE in patients with prostate cancer. The authors investigated the association of bevacizumab treatment and clinical factors with ATE/VTE risk in patients who were treated on Cancer and Leukemia Group B (CALGB) trial 90401. METHODS: Patients with metastatic, castration-resistant prostate cancer were randomized to receive docetaxel and prednisone with or without bevacizumab once every 21 days. Cycle-toevent Cox regression models were used to investigate the association of bevacizumab with the incidence of grade 3 or greater (3) ATE and VTE. Age, prior ATE/VTE, baseline antiplatelet/anticoagulant use, and VTE risk score (based on leukocyte count, hemoglobin, platelet count, body mass index, and tumor location) were evaluated in univariate and multivariable analyses. RESULTS: Of 1008 randomized patients, the odds of experiencing grade 3 ATE were significantly greater in those who received bevacizumab compared with those who received placebo (odds ratio, 2.79; P 5 .02), whereas an opposite trend was noted for grade 3 VTE (odds ratio, 0.60; P 5 .08). In the multivariable analysis, bevacizumab treatment (hazard ratio [HR], 3.00; P 5 .01) and age (HR, 1.06; P 5 .02) were significantly associated with the risk of ATE; whereas age (HR, 1.05; P 5 .01) and VTE risk score (HR, 1.83; P 5 .03) were significantly associated with the risk of VTE. CONCLUSIONS: Bevacizumab was significantly associated with a greater risk of ATE in patients with metastatic, castration-resistant prostate cancer, but it was not significantly associated with the risk of VTE. Understanding clinical factors that increase the risk for experiencing ATE/VTE is essential to mitigate the risks and reduce the burden of these prevalent complications in cancer care. Cancer 2015;121:1025-31.
INTRODUCTION
Bevacizumab is a humanized monoclonal antibody that targets the vascular endothelial growth factor (VEGF) and is currently approved to treat metastatic colorectal cancer, glioblastoma, metastatic renal cell carcinoma, and nonsquamous nonsmall cell lung cancer. [1] [2] [3] [4] [5] Although bevacizumab is generally well tolerated, common adverse drug events include hypertension and proteinuria, whereas rarer, more serious events include hemorrhaging and gastrointestinal (GI) perforation. [6] [7] [8] [9] [10] Patients with cancer are approximately 4 times more likely to experience a thromboembolism than those without cancer. 11 Clinical manifestations comprise arterial thromboembolism (ATE), including cardiac and cerebrovascular ischemia, and venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. The risk factors for ATE and VTE are distinct. Whereas the risk of ATE is increased by treatment with certain chemotherapeutic agents, 12 the risk of VTE may be increased by a variety of factors, such as chemotherapy and specific tumor types, including prostate cancer, 13 and by several patientspecific factors, including prior history, age, mobility, and diet. 14 Attesting to the array of influences on VTE is a predictive VTE risk score proposed and validated by Khorana et al that incorporates cancer site, hemoglobin, platelet count, leukocyte count, and body mass index (BMI) to stratify patients into low-risk, intermediate-risk, or highrisk categories for developing a VTE. 15 Bevacizumab has been associated with an increased risk of ATE. However, its effect on VTE remains controversial. 8, 9, [16] [17] [18] [19] A meta-analysis reporting an increased VTE risk with bevacizumab treatment 17 was refuted by 2 subsequent large pooled analyses. 8, 19 The objective our current report was to elucidate the influence of bevacizumab treatment and patientspecific factors on the risk of grade 3 or greater (3) ATE and VTE through Cancer and Leukemia Group B (CALGB) (Alliance) trial 90401, 20 a previously reported, large, randomized phase 3 study in patients with metastatic, castration-resistant prostate cancer who received docetaxel and prednisone with or without bevacizumab. Summary incidence rates from that trial suggested an increased rate of grade 3 ATE and a decreased rate of grade 3 VTE in bevacizumab-treated patients.
MATERIALS AND METHODS

Patient Selection
CALGB 90401 was a double-blinded phase 3 trial that randomized men with castration-resistant prostate cancer 1:1 to docetaxel and prednisone with and without bevacizumab. 20 All eligible patients were enrolled and treated on the CALGB 90401 study and provided institutional review board-approved, protocol-specific informed consent in accordance with federal and institutional guidelines. Briefly, patient eligibility included histologically documented, castration-resistant, progressive adenocarcinoma of the prostate. Relevant exclusion criteria included prior chemotherapy or antiangiogenic therapy, an Eastern Cooperative Oncology Group performance status >2, evidence of brain metastasis, congestive heart failure, uncontrolled hypertension, a GI bleed within the past 6 months, a GI perforation within the past 12 months, history of an ATE within the past 12 months, serious nonhealing ulcers or wounds, or grade 2 peripheral neuropathy.
Treatment
All patients received docetaxel 75 mg/m 2 as an intravenous infusion over 1 hour on day 1 of each 21-day cycle with oral dexamethasone before the docetaxel infusion plus oral prednisone 5 mg twice daily. Patients were equally randomized to receive bevacizumab 15 mg/kg or placebo as an intravenous infusion on day 1 of each 21-day cycle and were treated until disease progression, death, or a treatment-terminating adverse event occurred, for up to a maximum of 2 years of treatment. Stable doses of anticoagulants or antiplatelet therapy, including aspirin, were allowed. Bevacizumab or placebo was immediately discontinued for grade 4 hypertension, reversible leukoencephalopathy syndrome, recurrent ATE, grade 2 ATE, grade 3 hemorrhages or bleeding from any cause, GI perforation, wound dehiscence, or nephrotic syndrome.
Toxicity and Risk Factor Data Collection
Toxicity data were collected prospectively by the Alliance Statistics and Data Center at each treatment cycle on standardized forms that mandated reporting of all grade 3 toxicities as defined by the National Cancer Institute Common Toxicity Criteria for Adverse Events, Version 3.0. For this analysis, an ATE included any grade 3 cardiac ischemia/infarction or central nervous system ischemia, whereas VTE included any grade 3 thrombosis/thrombus/ embolism. Medical history was collected on standardized prestudy forms that included documentation of prior ATE (myocardial infarction, angina pectoris, peripheral vascular disease, arterial thrombosis, transient ischemic disease, and cerebrovascular accident) and prior VTE. Baseline antiplatelet/anticoagulant use was recorded along with dose and frequency. A validated predictive risk score for the incidence of VTE developed by Khorana et al 15 based on site of cancer (prostate, categorized as low risk), baseline platelet count (350,000/lL), hemoglobin (<10 g/dL), leukocyte count (>11,000/lL), and BMI (35 kg/m 2 ; all of which were collected prospectively) was used to classify patients into low-risk (zero risk factors), intermediate-risk (1-2 risk factors), or high-risk (3 risk factors) categories for developing a VTE.
Statistical Analysis
The primary endpoint was time (cycle) to the event of interest (ATE or VTE). The analyses for this endpoint were carried out under a competing-risks model in which the event of interest was subject to 3 dependent, informative censoring mechanisms: progression/death, other treatment-terminating adverse events, or "other reasons," such as loss to follow-up, withdrawal for reasons other Original Article than toxicity, or incomplete information (Table 1) . Patients who did not complete 2 years of therapy because of any of these competing risks before they experienced the event of interest were informatively censored at the cumulative bevacizumab cycles received. Given the competing risks, the time-to-event analyses were conducted on the basis of a cause-specific hazard for the influence of each covariate on the event of interest (VTE or ATE ). Cumulative incidence plots were constructed to observe the influence of bevacizumab treatment on the risk of ATE and VTE. Fisher exact tests 22 were used to assess baseline differences between bevacizumabtreated and placebo-treated patients. No adjustment for multiplicity testing was performed. Statistical analyses were conducted by the Alliance Statistics and Data Center on a data set that was locked on January 28, 2014.
RESULTS
Patients
The CALGB 90401 study randomized a total of 1050 patients, of whom 1008 received treatment (503 men received docetaxel, prednisone, and bevacizumab; 505 men received docetaxel, prednisone, and placebo). The median duration of therapy for both arms was 8 cycles. The median age for the entire cohort was 69 years. Approximately 68.2%, 31.1%, and 0.5% of patients were categorized as low risk, intermediate risk, and high risk based on the validated VTE risk score. The intermediate-risk and high-risk categories were collapsed for the univariate and multivariable analysis because of the low number of high-risk patients. At study entry, most patients (59.5%) were using aspirin, a different antiplatelet, or an anticoagulant, whereas 12.8% and 3.8% of patients had a positive history of a prior ATE and VTE, respectively. The baseline factors between bevacizumab-treated and placebo-treated patients were similar (Table 2) . Of the total population, 26 patients experienced grade 3 ATE, and 58 patients experienced grade 3 VTE. Table 1 describes the number of patients who experienced each competing-risk event.
Influence of Bevacizumab on the Risk of ATE
The cause-specific univariate analysis of the cycle-to-event Cox regression model confirmed previous reports that bevacizumab treatment significantly increased the risk of ATE compared with placebo (cause-specific hazard ratio [HR], 2.70; 95% confidence interval [CI], 1.14-6.43; P 5 .02). Figure 1 illustrates the cumulative incidence of grade 3 ATE by treatment cycle stratified according to treatment arm. The incidence of grade 3 ATE in the bevacizumabtreated and placebo-treated patients was 3.8% and 1.4%, respectively (odds ratio [OR], 2.79; P 5 .02).
Influence of Bevacizumab on the Risk of VTE
The cause-specific univariate analysis of the cycle-to-event Cox regression model demonstrated a trend toward a decreased risk of VTE in bevacizumab-treated patients compared with placebo-treated patients (HR, 0.60; 95% CI, 0.35-1.02; P 5 .06). Figure 2 illustrates the cumulative incidence of grade 3 VTE by treatment cycle stratified according to treatment arm. The incidence of grade 3 VTE in bevacizumab-treated and placebo-treated patients was 4.4% and 7.1%, respectively (odds ratio, 0.6; P 5 .08). Table 3 . Both treatment with bevacizumab (HR, 3.00; 95% CI, 1.25-7.19; P 5 .01) and increasing age (HR, 1.06; 95% CI, 1.01-1.12; P 5 .02) remained significant for an association with increased risk of grade 3 ATE, whereas prior ATE no longer met statistical significance (HR, 2.29; 95% CI, 0.93-5.68; P 5 .07). Both increasing age (HR, 1.05; 95% CI, 1.01-1.08; P 5 .01) and VTE risk score (HR, 1.83; 95% CI, 1.07-3.14; P 5 .03), but not bevacizumab treatment (HR, 0.66; 95% CI, 0.38-1.12; P 5 .13), were significantly associated with the risk of grade 3 VTE in the multivariable model.
DISCUSSION
Our analyses confirmed previous data indicating that patients who received bevacizumab were at a significantly greater risk of experiencing grade 3 ATE compared with patients who received placebo. The incidence of grade 3 ATE among patients who did and did not receive bevacizumab (3.8% and 1.4%, respectively) is consistent with the rates from a previously reported pooled analysis of 1745 patients with metastatic cancer (data for bevacizumab-treated patients with prostate cancer were not previously available) of 3.8% and 1.7% in the bevacizumab and control populations, respectively. 8 In univariate analysis, a potential protective effect of bevacizumab on the risk of VTE was identified. The VTE incidence rates in this study, 4.4% and 7.1% for Figure 1 . This is a cumulative incidence curve for grade 3 or greater (3) arterial thromboembolism (ATE) stratified by treatment arm. There were 19 events among 503 patients (3.78%) in the bevacizumab arm and 7 events among 505 patients (1.39%) in the placebo arm. The hazard ratio for the cumulative incidence of grade 3 ATE in the patients who received bevacizumab was 2.76 (95% confidence interval, 1.16-6.55; P 5 .021). Figure 2 . This is a cumulative incidence curve for grade 3 or greater (3) venous thromboembolism (VTE) stratified by treatment arm. There were 22 events among 503 patients (4.37%) in the bevacizumab arm and 36 events among 505 patients (7.13%) in the placebo arm. The hazard ratio for the cumulative incidence of grade 3 VTE in the patients who received bevacizumab was 0.60 (95% confidence interval, 0.35-1.02; P 5 .059).
bevacizumab-treated and placebo-treated patients, respectively, are lower than those reported (10.9% and 9.8%, respectively) in a prior pooled analysis; however, the incidence rates of grade 3 VTE vary greatly across tumor types and treatment regimens (range, 1.2%-13.6%). 19 A prior analysis of 6055 patients reported lower rates of VTE in bevacizumab-treated patients when adjusted by exposure and proposed that patients who receive bevacizumab may experience better tumor control, resulting in decreased tumor-related complications, such as VTE. In CALGB 90401, the patients who received bevacizumab had superior progression-free survival, prostate-specific antigen response, and objective response but did not have superior overall survival. 20 Because VTE is a well documented tumor-related complication, 14 it is possible that the tumor control benefit of bevacizumab treatment partially explains the suggested protective effect on VTE.
Given the lack of data on clinical risk factors associated with ATE and VTE in patients with prostate cancer, we assessed the influence of baseline covariates on the risk of ATE and VTE.
In multivariable analysis, bevacizumab treatment and increasing age were statistically significant predictors of increased ATE risk, whereas there was a trend toward an increased risk in patients with prior ATE. These data are consistent with a previously reported pooled analysis by Scappaticci et al. 8 Alternatively, both increasing age and VTE risk score had statistically significant associations with an increased risk of VTE. A previously published pooled analysis by Hurwitz et al 19 demonstrated that age, prior VTE, and coumarin use at baseline were associated with increased VTE risk. It is possible that the relatively low number of patients with prior VTE events reported in our population prevented the replication of this finding. Only a minority of baseline antiplatelet/anticoagulant users were receiving coumarins, which also may have prevented the replication of similar findings. However, to our knowledge, our report is the first to validate the VTE risk score 15 in a homogenous cohort of patients with 1 tumor type from a randomized phase 3 study using a competingrisks model. It is noteworthy that accounting for age and VTE risk score further abrogated the apparent protective effect of bevacizumab on the risk of VTE.
Our approach of using a competing-risks model accounted for informative intervening events that may interfere with the observed event of interest. By definition, the informative censoring approach and removal of patients from being subject to the event of interest (ie, ATE/VTE) will result in a lower cumulative incidence. 23 Failure to account for informative censoring may result in a falsely overestimated cumulative incidence, which may be substantial when the competing-risk event is related to the underlying disease. 24 Use of this method allowed for a more principled interpretation of ATE and VTE risk compared with previous studies, which generally have used the traditional Kaplan-Meier approach and may have overestimated the risk.
Although bevacizumab does not have a standard role in current prostate cancer treatment paradigms, 20 these findings still have clinical applicability both within and beyond this tumor type. Bevacizumab is used in the firstline setting for many other tumor types, underscoring the need to understand the adverse event profile of this agent, in particular its influence on rates of rare but severe adverse events like ATE. In addition, our report provides the first known analysis of the covariates that influence VTE risk in patients receiving docetaxel and prednisone, a standard first-line chemotherapy regimen for metastatic, castration-resistant prostate cancer. Recognizing patients with prostate cancer who are at high risk for developing VTE (eg, older patients and those with a higher VTE risk score) is vital for improving patient safety and identifying patients for thromboprophylaxis. American Society of Clinical Oncology practice guidelines for VTE prophylaxis 14 support the VTE risk score proposed by Khorana et al 15 to identify high-risk patients in the outpatient setting. Although routine thromboprophylaxis is not currently recommended in this setting, the balance of benefit and harm with thromboprophylaxis for high-risk patients identified by the model is currently under study (national clinical trials NCT00876915 and NCT02048865). Nevertheless, it is critical that clinicians actively engage patients in discussion about the signs and symptoms of VTE, particularly those who are at higher risk.
In conclusion, our analysis from a large, prospective cohort of patients with metastatic, castration-resistant prostate cancer who received docetaxel and prednisone with or without bevacizumab confirms the increased risk of grade 3 ATE from bevacizumab treatment. We observed that increasing age was significantly associated with an increased risk of experiencing grade 3 ATE; whereas increasing age and VTE risk score, but not treatment with bevacizumab, were significantly associated with an increased risk of experiencing grade 3 VTE. Understanding the risk factors for ATE and VTE is essential to mitigate the risks and reduce the burden of these prevalent complications in cancer care.
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